ncRNADrug: a database for validated and predicted ncRNAs associated with drug resistance and targeted by drugs
Nucleic Acids Research · 05.01.2024 · 52 (D1) · D1393-D1399
DOI: 10.1093/nar/gkad1042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 11.11.2023. Verfasst von Xinyu Cao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Fujian Key Laboratory of Precision Medicine for Cancer, the First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China. Hauptthemen laut MEDLINE: MicroRNAs, Neoplasms, RNA, Long Noncoding. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Drug resistance is a major barrier in cancer treatment and anticancer drug development. Growing evidence indicates that non-coding RNAs (ncRNAs), especially microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), play pivotal roles in cancer progression, therapy, and drug resistance. Furthermore, ncRNAs have been proven to be promising novel therapeutic targets for cancer treatment. Reversing dysregulated ncRNAs by drugs holds significant potential as an effective therapeutic strategy for overcoming drug resistance. Therefore, we developed ncRNADrug, an integrated and comprehensive resource that records manually curated and computationally predicted ncRNAs associated with drug resistance, ncRNAs targeted by drugs, as well as potential drug combinations for the treatment of resistant cancer. Currently, ncRNADrug collects 29 551 experimentally validated entries involving 9195 ncRNAs (2248 miRNAs, 4145 lncRNAs and 2802 circRNAs) associated with the drug resistance of 266 drugs, and 32 969 entries involving 10 480 ncRNAs (4338 miRNAs, 6087 lncRNAs and 55 circRNAs) targeted by 965 drugs. In addition, ncRNADrug also contains associations between ncRNAs and drugs predicted from ncRNA expression profiles by differential expression analysis. Altogether, ncRNADrug surpasses the existing related databases in both data volume and functionality. It will be a useful resource for drug development and cancer treatment. ncRNADrug is available at http://www.jianglab.cn/ncRNADrug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Fujian Key Laboratory of Precision Medicine for Cancer, the First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China.
- Department of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing 211106, China.
- Department of Thoracic Surgery and West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu 610041, China.
ORCID-Profile: Wei Jiang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Cao, X., Zhou, X., Hou, F., Huang, Y. E., Yuan, M., Long, M., Chen, S., Lei, W., Zhu, J., Chen, J., Zhang, T., Guo, A. Y., & Jiang, W. (2024). ncRNADrug: a database for validated and predicted ncRNAs associated with drug resistance and targeted by drugs. Nucleic Acids Research, 52(D1), D1393-D1399. https://doi.org/10.1093/nar/gkad1042
Vancouver
Cao X, Zhou X, Hou F, Huang YE, Yuan M, Long M, et al. ncRNADrug: a database for validated and predicted ncRNAs associated with drug resistance and targeted by drugs. Nucleic Acids Research. 2024;52(D1):D1393-D1399. doi:10.1093/nar/gkad1042
BibTeX
@article{Cao2024,
author = {Cao, Xinyu and Zhou, Xu and Hou, Fei and Huang, Yu-E and Yuan, Mengqin and Long, Min and Chen, Sina and Lei, Wanyue and Zhu, Jicun and Chen, Jiahao and Zhang, Tao and Guo, An-Yuan and Jiang, Wei},
title = {ncRNADrug: a database for validated and predicted ncRNAs associated with drug resistance and targeted by drugs},
journal = {Nucleic Acids Research},
year = {2024},
volume = {52},
number = {D1},
pages = {D1393--D1399},
doi = {10.1093/nar/gkad1042}
}
EUVIMED